REGENTIS BIOMATERIALS LTD. RGNT

Healthcare SIC 3842 - Orthopedic, Prosthetic & Surgical Appliances & Supplies NAICS Manufacturing › Miscellaneous Manufacturing › Medical Equipment and Supplies Manufacturing › Surgical Appliance and Supplies Manufacturing derived NYSE

Last close —
Market cap —
52-week range — - —

No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-24.16

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022
SG&A $6.6M$712.0K$1.1M—
Operating income -$7.0M$932.0K-$1.9M—
Pre-tax income $13.6M-$4.8M$4.1M—
Net income -$13.6M$4.8M-$4.1M—
EPS, basic -24.161.72-24.09—
EPS, diluted -24.161.72-24.09—
Shares, diluted (wtd. avg.) 566,7442.8M173,508—

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022
Cash and equivalents $7.4M———
Total assets $7.6M$482.0K——
Short-term debt $1.2M$573.0K$325.0K—
Total current liabilities $2.9M$6.5M——
Total liabilities $2.9M$6.5M——
Retained earnings -$55.8M-$42.1M——
Total equity $4.7M-$41.1M-$45.9M-$42.1M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022
Operating cash flow -$1.4M-$641.0K-$1.2M—
Stock-based compensation $7.0M———
Financing cash flow $8.5M$525.0K$325.0K—

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-021722.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
Operating cash flow by fiscal year, in US dollars The same figures are in the table below this chart. -1.5M -1M -500K 0 Operating cash flow, FY2023: -1.2M Operating cash flow, FY2024: -641K Operating cash flow, FY2025: -1.4M FY2022 FY2023 FY2024 FY2025
Fiscal year FY2022FY2023FY2024FY2025
Operating cash flow — -$1.2M -$641.0K -$1.4M

Others in SIC 3842

TickerCompanyMarket capP/ERevenue growth
ISRG INTUITIVE SURGICAL INC $129.55B 46.6x 20.5%
EW Edwards Lifesciences Corp $51.82B 49.1x 11.5%
STE STERIS plc $21.90B 28.3x 8.7%
ZBH ZIMMER BIOMET HOLDINGS, INC. $18.71B 27.6x 7.2%
ALGN ALIGN TECHNOLOGY INC $11.27B 28.1x 0.9%
MSA MSA Safety Inc $7.28B 26.6x 3.7%
ESTA ESTABLISHMENT LABS HOLDINGS INC. $2.21B — 27.1%
CDRE Cadre Holdings, Inc. $1.27B 29.2x 7.5%